理解新生儿脓毒症全球抗菌药物使用与耐药模式:NeoAMR网络洞察
该研究通过基于REDCap数据库的网络调查,覆盖12个国家39个新生儿病房,了解中低收入国家新生儿病房资源与临床实践差异,以指导单位级抗菌药物耐药负担观察研究的设计。结果显示各病房在活产数、床位、早产收治比例、经验性抗菌药物选择及耐药率方面差异显著,革兰阴性菌头孢菌素耐药率26%至84%,碳青霉烯耐药率0%至81%,革兰阳性菌糖肽类耐药率0%至45%。结论认为抗菌药物耐药在中低收入国家新生儿病房已是重要问题,且病房间差异显著,设计干预措施时需考虑这些差异。
要点
- 39个新生儿病房中66%以基本药物清单「可及」类抗菌药物作为新生儿脓毒症一线治疗。
- 革兰阴性菌头孢菌素耐药率范围26%至84%,碳青霉烯耐药率范围0%至81%。
- 革兰阳性菌糖肽类耐药率范围0%至45%,病房间差异显著。
核心结论
- 抗菌药物耐药在中低收入国家新生儿病房已是重要问题,且不同病房间差异显著,设计改善全球新生儿死亡率的干预措施时必须考虑这些差异。
研究设计与样本
- 采用基于REDCap数据库的网络调查,发放给参与新生儿抗菌药物耐药研究网络的新生儿病房,调查内容包括病房资金结构、规模、收治率、支持治疗可及性、经验性抗菌药物指南及新生儿血培养分离株和耐药模式的期间患病率。
- 研究覆盖12个国家的39个新生儿病房,纳入收治于参与病房的任何新生儿。
- 研究为观察性队列研究。
主要发现
- 胎龄小于32周早产儿收治比例范围为0%至19%。
- 多数病房(26/39,66%)以基本药物清单「可及」类抗菌药物作为新生儿脓毒症一线治疗。
- 革兰阴性菌分离株头孢菌素耐药率范围为26%至84%,碳青霉烯耐药率范围为0%至81%。
- 革兰阳性菌分离株糖肽类耐药率范围为0%至45%。
关键数值与推荐
- 胎龄小于32周早产儿收治比例范围为0%至19%。
- 26/39(66%)病房以基本药物清单「可及」类抗菌药物作为新生儿脓毒症一线治疗。
- 革兰阴性菌头孢菌素耐药率范围为26%至84%,碳青霉烯耐药率范围为0%至81%。
- 革兰阳性菌糖肽类耐药率范围为0%至45%。
临床怎么用
- 在解读某新生儿病房抗菌药物耐药负担时,需考虑该病房资金结构、规模、收治率、支持治疗可及性及经验性抗菌药物指南等病房层面因素的显著差异。
- 设计改善新生儿死亡率的全球干预措施时,应考虑中低收入国家新生儿病房间抗菌药物使用与耐药模式的巨大变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To gain an understanding of the variation in available resources and clinical practices between neonatal units (NNUs) in the low-income and middle-income country (LMIC) setting to inform the design of an observational study on the burden of unit-level antimicrobial resistance (AMR). DESIGN: A web-based survey using a REDCap database was circulated to NNUs participating in the Neonatal AMR research network. The survey included questions about NNU funding structure, size, admission rates, access to supportive therapies, empirical antimicrobial guidelines and period prevalence of neonatal blood culture isolates and their resistance patterns. SETTING: 39 NNUs from 12 countries. PATIENTS: Any neonate admitted to one of the participating NNUs. INTERVENTIONS: This was an observational cohort study. RESULTS: The number of live births per unit ranged from 513 to 27 700 over the 12-month study period, with the number of neonatal cots ranging from 12 to 110. The proportion of preterm admissions <32 weeks ranged from 0% to 19%, and the majority of units (26/39, 66%) use Essential Medicines List 'Access' antimicrobials as their first-line treatment in neonatal sepsis. Cephalosporin resistance rates in Gram-negative isolates ranged from 26% to 84%, and carbapenem resistance rates ranged from 0% to 81%. Glycopeptide resistance rates among Gram-positive isolates ranged from 0% to 45%. CONCLUSION: AMR is already a significant issue in NNUs worldwide. The apparent burden of AMR in a given NNU in the LMIC setting can be influenced by a range of factors which will vary substantially between NNUs. These variations must be considered when designing interventions to improve neonatal mortality globally.
引用
- Li G, Bielicki JA, Ahmed ASMNU, et al. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child. 2019. PMID: 31446393. doi:10.1136/archdischild-2019-316816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。